|
1
|
Wray CJ, Ahmad SA, Matthews JB and Lowy
AM: Surgery for pancreatic cancer: recent controversies and current
practice. Gastroenterology. 128:1626–1641. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cameron JL, Riall TS, Coleman J and
Belcher KA: One thousand consecutive pancreaticoduodenectomies. Ann
Surg. 244:10–15. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raman SP, Horton KM, Cameron JL and
Fishman EK: CT after pancreaticoduodenectomy: spectrum of normal
findings and complications. AJR Am J Roentgenol. 201:2–13. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Loehrer PJ Sr, Feng Y, Cardenes H, et al:
Gemcitabine alone versus gemcitabine plus radiotherapy in patients
with locally advanced pancreatic cancer: an Eastern Cooperative
Oncology Group trial. J Clin Oncol. 29:4105–4112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colucci G, Labianca R, Di Costanzo F, et
al: Randomized phase III trial of gemcitabine plus cisplatin
compared with single-agent gemcitabine as first-line treatment of
patients with advanced pancreatic cancer: the GIP-1 study. J Clin
Oncol. 28:1645–1651. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cunningham D, Chau I, Stocken DD, et al:
Phase III randomized comparison of gemcitabine versus gemcitabine
plus capecitabine in patients with advanced pancreatic cancer. J
Clin Oncol. 27:5513–5518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Conroy T, Desseigne F, Ychou M, et al:
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N
Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Von Hoff DD, Ervin T, Arena FP, et al:
Increased survival in pancreatic cancer with nab-paclitaxel plus
gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bachem MG, Schneider E, Gross H, et al:
Identification, culture, and characterization of pancreatic
stellate cells in rats and humans. Gastroenterology. 115:421–432.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Apte MV, Haber PS, Applegate TL, et al:
Periacinar stellate shaped cells in rat pancreas: identification,
isolation, and culture. Gut. 43:128–133. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujita H, Ohuchida K, Mizumoto K, et al:
Tumor-stromal interactions with direct cell contacts enhance
proliferation of human pancreatic carcinoma cells. Cancer Sci.
100:2309–2317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vonlaufen A, Joshi S, Qu C, et al:
Pancreatic stellate cells: partners in crime with pancreatic cancer
cells. Cancer Res. 68:2085–2093. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hwang RF, Moore T, Arumugam T, et al:
Cancer-associated stromal fibroblasts promote pancreatic tumor
progression. Cancer Res. 68:918–926. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mantoni TS, Lunardi S, Al-Assar O,
Masamune A and Brunner TB: Pancreatic stellate cells radioprotect
pancreatic cancer cells through β1-integrin signaling. Cancer Res.
71:3453–3458. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Farrow B, Berger DH and Rowley D:
Tumor-derived pancreatic stellate cells promote pancreatic cancer
cell invasion through release of thrombospondin-2. J Surg Res.
156:155–160. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Greenwald I and Kovall R: Notch signaling:
genetics and structure. WormBook. 1–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nicolas M, Wolfer A, Raj K, et al: Notch1
functions as a tumor suppressor in mouse skin. Nat Genet.
33:416–421. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Radtke F and Raj K: The role of Notch in
tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer.
3:756–767. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mann CD, Bastianpillai C, Neal CP, et al:
Notch3 and HEY-1 as prognostic biomarkers in pancreatic
adenocarcinoma. PLoS One. 7:e511192012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yabuuchi S, Pai SG, Campbell NR, et al:
Notch signaling pathway targeted therapy suppresses tumor
progression and metastatic spread in pancreatic cancer. Cancer
Lett. 335:41–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mizuma M, Rasheed ZA, Yabuuchi S, et al:
The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer
growth in preclinical models. Mol Cancer Ther. 11:1999–2009. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cook N, Frese KK, Bapiro TE, et al: Gamma
secretase inhibition promotes hypoxic necrosis in mouse pancreatic
ductal adenocarcinoma. J Exp Med. 209:437–444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schott AF, Landis MD, Dontu G, et al:
Preclinical and clinical studies of gamma secretase inhibitors with
docetaxel on human breast tumors. Clin Cancer Res. 19:1512–1524.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamada S, Fuchs BC, Fujii T, et al:
Epithelial-to-mesenchymal transition predicts prognosis of
pancreatic cancer. Surgery. 154:946–954. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Van Cutsem E, van de Velde H, Karasek P,
et al: Phase III trial of gemcitabine plus tipifarnib compared with
gemcitabine plus placebo in advanced pancreatic cancer. J Clin
Oncol. 22:1430–1438. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abou-Alfa GK, Letourneau R, Harker G, et
al: Randomized phase III study of exatecan and gemcitabine compared
with gemcitabine alone in untreated advanced pancreatic cancer. J
Clin Oncol. 24:4441–4447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Heinemann V, Quietzsch D, Gieseler F, et
al: Randomized phase III trial of gemcitabine plus cisplatin
compared with gemcitabine alone in advanced pancreatic cancer. J
Clin Oncol. 24:3946–3952. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Van Cutsem E, Vervenne WL, Bennouna J, et
al: Phase III trial of bevacizumab in combination with gemcitabine
and erlotinib in patients with metastatic pancreatic cancer. J Clin
Oncol. 27:2231–2237. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ueno H, Ioka T, Ikeda M, et al: Randomized
phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine
alone in patients with locally advanced and metastatic pancreatic
cancer in Japan and Taiwan: GEST study. J Clin Oncol. 31:1640–1648.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vaccaro V, Sperduti I and Milella M:
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N
Engl J Med. 365:768–769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Louvet C, Labianca R, Hammel P, et al:
Gemcitabine in combination with oxaliplatin compared with
gemcitabine alone in locally advanced or metastatic pancreatic
cancer: results of a GERCOR and GISCAD phase III trial. J Clin
Oncol. 23:3509–3516. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Colucci G, Giuliani F, Gebbia V, et al:
Gemcitabine alone or with cisplatin for the treatment of patients
with locally advanced and/or metastatic pancreatic carcinoma: a
prospective, randomized phase III study of the Gruppo Oncologia
dell’Italia Meridionale. Cancer. 94:902–910. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McCarroll JA, Naim S, Sharbeen G, et al:
Role of pancreatic stellate cells in chemoresistance in pancreatic
cancer. Front Physiol. 5:1412014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kikuta K, Masamune A, Watanabe T, et al:
Pancreatic stellate cells promote epithelial-mesenchymal transition
in pancreatic cancer cells. Biochem Biophys Res Commun.
403:380–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Izumiya M, Kabashima A, Higuchi H, et al:
Chemoresistance is associated with cancer stem cell-like properties
and epithelial-to-mesenchymal transition in pancreatic cancer
cells. Anticancer Res. 32:3847–3853. 2012.PubMed/NCBI
|
|
37
|
Gungor C, Zander H, Effenberger KE, et al:
Notch signaling activated by replication stress-induced expression
of midkine drives epithelial-mesenchymal transition and
chemoresistance in pancreatic cancer. Cancer Res. 71:5009–5019.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Z, Li Y, Kong D, et al: Acquisition
of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kang M, Jiang B, Xu B, et al: Delta like
ligand 4 induces impaired chemo-drug delivery and enhanced
chemoresistance in pancreatic cancer. Cancer Lett. 330:11–21. 2013.
View Article : Google Scholar
|
